Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.

Mao W, Ghasemzadeh A, Freeman ZT, Obradovic A, Chaimowitz MG, Nirschl TR, McKiernan E, Yegnasubramanian S, Drake CG.

J Immunother Cancer. 2019 Oct 25;7(1):277. doi: 10.1186/s40425-019-0758-y.

2.

Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis.

Porter CM, Haffner MC, Kulac I, Maynard JP, Baena-Del Valle JA, Isaacs WB, Yegnasubramanian S, De Marzo AM, Sfanos KS.

Am J Pathol. 2019 Nov;189(11):2311-2322. doi: 10.1016/j.ajpath.2019.07.016. Epub 2019 Sep 6.

PMID:
31499027
3.

Publisher Correction: Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers.

Ando M, Saito Y, Xu G, Bui NQ, Medetgul-Ernar K, Pu M, Fisch K, Ren S, Sakai A, Fukusumi T, Liu C, Haft S, Pang J, Mark A, Gaykalova DA, Guo T, Favorov AV, Yegnasubramanian S, Fertig EJ, Ha P, Tamayo P, Yamasoba T, Ideker T, Messer K, Califano JA.

Nat Commun. 2019 May 29;10(1):2415. doi: 10.1038/s41467-019-10557-7.

4.

A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs.

Giovinazzo H, Walker D, Wyhs N, Liu J, Esopi DM, Vaghasia AM, Jain Y, Bhamidipati A, Zhou J, Nelson WG, Yegnasubramanian S.

Oncotarget. 2019 Apr 30;10(32):3040-3050. doi: 10.18632/oncotarget.26889. eCollection 2019 Apr 30.

5.

Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers.

Ando M, Saito Y, Xu G, Bui NQ, Medetgul-Ernar K, Pu M, Fisch K, Ren S, Sakai A, Fukusumi T, Liu C, Haft S, Pang J, Mark A, Gaykalova DA, Guo T, Favorov AV, Yegnasubramanian S, Fertig EJ, Ha P, Tamayo P, Yamasoba T, Ideker T, Messer K, Califano JA.

Nat Commun. 2019 May 16;10(1):2188. doi: 10.1038/s41467-019-09937-w. Erratum in: Nat Commun. 2019 May 29;10(1):2415.

6.

Defining UHRF1 Domains that Support Maintenance of Human Colon Cancer DNA Methylation and Oncogenic Properties.

Kong X, Chen J, Xie W, Brown SM, Cai Y, Wu K, Fan D, Nie Y, Yegnasubramanian S, Tiedemann RL, Tao Y, Chiu Yen RW, Topper MJ, Zahnow CA, Easwaran H, Rothbart SB, Xia L, Baylin SB.

Cancer Cell. 2019 Apr 15;35(4):633-648.e7. doi: 10.1016/j.ccell.2019.03.003. Epub 2019 Apr 4.

PMID:
30956060
7.

Consequences of interleukin 1β-triggered chronic inflammation in the mouse prostate gland: Altered architecture associated with prolonged CD4+ infiltration mimics human proliferative inflammatory atrophy.

Ashok A, Keener R, Rubenstein M, Stookey S, Bajpai S, Hicks J, Alme AK, Drake CG, Zheng Q, Trabzonlu L, Yegnasubramanian S, De Marzo AM, Bieberich CJ.

Prostate. 2019 May;79(7):732-745. doi: 10.1002/pros.23784. Epub 2019 Mar 22.

PMID:
30900284
8.

If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease.

Sfanos KS, Yegnasubramanian S, Nelson WG, Lotan TL, Kulac I, Hicks JL, Zheng Q, Bieberich CJ, Haffner MC, De Marzo AM.

Asian J Urol. 2019 Jan;6(1):10-25. doi: 10.1016/j.ajur.2018.11.006. Epub 2018 Dec 12. Review.

9.

Transcriptional profiling identifies novel regulators of macrophage polarization.

Gerrick KY, Gerrick ER, Gupta A, Wheelan SJ, Yegnasubramanian S, Jaffee EM.

PLoS One. 2018 Dec 7;13(12):e0208602. doi: 10.1371/journal.pone.0208602. eCollection 2018.

10.

CD38 is methylated in prostate cancer and regulates extracellular NAD.

Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, Sboner A, Bareja R, Esopi D, Isaacs WB, Yegnasubramanian S, Rettig MB, Elashoff DA, Platz EA, De Marzo AM, Teitell MA, Goldstein AS.

Cancer Metab. 2018 Sep 21;6:13. doi: 10.1186/s40170-018-0186-3. eCollection 2018.

11.

Redox-Responsive Nanoparticle-Mediated Systemic RNAi for Effective Cancer Therapy.

Xu X, Wu J, Liu S, Saw PE, Tao W, Li Y, Krygsman L, Yegnasubramanian S, De Marzo AM, Shi J, Bieberich CJ, Farokhzad OC.

Small. 2018 Oct;14(41):e1802565. doi: 10.1002/smll.201802565. Epub 2018 Sep 17.

12.

Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors.

Haffner MC, Taheri D, Luidy-Imada E, Palsgrove DN, Eich ML, Netto GJ, Matoso A, Nirschl TR, Zheng Q, Hicks JL, Nelson WG, De Marzo AM, Marchionni L, Drake CG, Yegnasubramanian S.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8580-E8582. doi: 10.1073/pnas.1803292115. Epub 2018 Sep 4. No abstract available.

13.

Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities.

Trabzonlu L, Kulac I, Zheng Q, Hicks JL, Haffner MC, Nelson WG, Sfanos KS, Ertunc O, Lotan TL, Heaphy CM, Meeker AK, Yegnasubramanian S, De Marzo AM.

Cold Spring Harb Perspect Med. 2019 Apr 1;9(4). pii: a030403. doi: 10.1101/cshperspect.a030403. Review.

PMID:
30082453
14.

Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.

Yegnasubramanian S, De Marzo AM, Nelson WG.

Cold Spring Harb Perspect Med. 2019 Apr 1;9(4). pii: a030445. doi: 10.1101/cshperspect.a030445. Review.

PMID:
29959132
15.

Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate.

Markowski MC, Hubbard GK, Hicks JL, Zheng Q, King A, Esopi D, Rege A, Yegnasubramanian S, Bieberich CJ, De Marzo AM.

Prostate. 2018 Sep;78(13):992-1000. doi: 10.1002/pros.23657. Epub 2018 May 30.

PMID:
29851094
16.

ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.

Torres A, Alshalalfa M, Davicioni E, Gupta A, Yegnasubramanian S, Wheelan SJ, Epstein JI, De Marzo AM, Lotan TL.

Prostate. 2018 Sep;78(12):896-904. doi: 10.1002/pros.23646. Epub 2018 May 15.

17.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712
18.

The structure of the nucleus in normal and neoplastic prostate cells: untangling the role of type 2 DNA topoisomerases.

Nelson WG, Haffner MC, Yegnasubramanian S.

Am J Clin Exp Urol. 2018 Apr 1;6(2):107-113. eCollection 2018. Review.

19.

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.

Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan TL, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, Yegnasubramanian S, Luo J, Mehra R, Antonarakis ES, Drake CG, De Marzo AM.

Am J Pathol. 2018 Jun;188(6):1478-1485. doi: 10.1016/j.ajpath.2018.02.014. Epub 2018 Mar 22.

20.

The inflammatory microenvironment and microbiome in prostate cancer development.

Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM.

Nat Rev Urol. 2018 Jan;15(1):11-24. doi: 10.1038/nrurol.2017.167. Epub 2017 Oct 31. Review.

PMID:
29089606
21.

MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.

Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ, Meeker AK, Heaphy CM, Graham MK, De Marzo AM.

J Pathol. 2018 Jan;244(1):11-24. doi: 10.1002/path.4980. Epub 2017 Nov 14.

22.

Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer.

Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, Yegnasubramanian S, Mangold LA, Partin AW, Sfanos KS.

J Urol. 2018 Jan;199(1):161-171. doi: 10.1016/j.juro.2017.08.001. Epub 2017 Aug 7.

23.

AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination.

Haffner MC, Esopi DM, Chaux A, Gürel M, Ghosh S, Vaghasia AM, Tsai H, Kim K, Castagna N, Lam H, Hicks J, Wyhs N, Biswal Shinohara D, Hurley PJ, Simons BW, Schaeffer EM, Lotan TL, Isaacs WB, Netto GJ, De Marzo AM, Nelson WG, An SS, Yegnasubramanian S.

Nat Commun. 2017 Jul 26;8(1):142. doi: 10.1038/s41467-017-00084-8.

24.

A Novel Functional Splice Variant of AKT3 Defined by Analysis of Alternative Splice Expression in HPV-Positive Oropharyngeal Cancers.

Guo T, Sakai A, Afsari B, Considine M, Danilova L, Favorov AV, Yegnasubramanian S, Kelley DZ, Flam E, Ha PK, Khan Z, Wheelan SJ, Gutkind JS, Fertig EJ, Gaykalova DA, Califano J.

Cancer Res. 2017 Oct 1;77(19):5248-5258. doi: 10.1158/0008-5472.CAN-16-3106. Epub 2017 Jul 21.

25.

Inflammation, Microbiota, and Prostate Cancer.

Puhr M, De Marzo A, Isaacs W, Lucia MS, Sfanos K, Yegnasubramanian S, Culig Z.

Eur Urol Focus. 2016 Oct;2(4):374-382. doi: 10.1016/j.euf.2016.08.010. Epub 2016 Aug 28. Review.

PMID:
28723469
26.

Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations.

Mattox AK, Wang Y, Springer S, Cohen JD, Yegnasubramanian S, Nelson WG, Kinzler KW, Vogelstein B, Papadopoulos N.

Proc Natl Acad Sci U S A. 2017 May 2;114(18):4733-4738. doi: 10.1073/pnas.1701382114. Epub 2017 Apr 17.

27.

c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.

Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG.

EBioMedicine. 2017 Apr;18:83-93. doi: 10.1016/j.ebiom.2017.04.006. Epub 2017 Apr 5.

28.

Genetic landscape of extreme responders with anaplastic oligodendroglioma.

Holdhoff M, Cairncross GJ, Kollmeyer TM, Zhang M, Zhang P, Mehta MP, Werner-Wasik M, Souhami L, Bahary JP, Kwok Y, Hartford AC, Chakravarti A, Yegnasubramanian S, Vogelstein B, Papadopoulos N, Kinzler K, Jenkins RB, Bettegowda C.

Oncotarget. 2017 May 30;8(22):35523-35531. doi: 10.18632/oncotarget.16773.

29.

Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.

Ajiboye AS, Esopi D, Yegnasubramanian S, Denmeade SR.

Prostate. 2017 Jun;77(8):829-837. doi: 10.1002/pros.23323. Epub 2017 Feb 22.

30.

Prostate cancer epigenetics and its clinical implications.

Yegnasubramanian S.

Asian J Androl. 2016 Jul-Aug;18(4):549-58. doi: 10.4103/1008-682X.179859. Review.

31.

Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors.

Anders NM, Liu J, Wanjiku T, Giovinazzo H, Zhou J, Vaghasia A, Nelson WG, Yegnasubramanian S, Rudek MA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jun 1;1022:38-45. doi: 10.1016/j.jchromb.2016.03.029. Epub 2016 Mar 21.

32.

Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.

Gondek LP, Zheng G, Ghiaur G, DeZern AE, Matsui W, Yegnasubramanian S, Lin MT, Levis M, Eshleman JR, Varadhan R, Tucker N, Jones R, Gocke CD.

Leukemia. 2016 Sep;30(9):1916-1920. doi: 10.1038/leu.2016.63. Epub 2016 Mar 15. No abstract available.

33.

Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.

Hedayati M, Haffner MC, Coulter JB, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Razavi N, Dalrymple S, Isaacs JT, Santos A, Hales R, Nelson WG, Yegnasubramanian S, DeWeese TL.

Clin Cancer Res. 2016 Jul 1;22(13):3310-3319. doi: 10.1158/1078-0432.CCR-15-1147. Epub 2016 Feb 1.

34.

Premalignancy in Prostate Cancer: Rethinking What we Know.

De Marzo AM, Haffner MC, Lotan TL, Yegnasubramanian S, Nelson WG.

Cancer Prev Res (Phila). 2016 Aug;9(8):648-56. doi: 10.1158/1940-6207.CAPR-15-0431. Epub 2016 Jan 26. Review.

35.

Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies.

Munari E, Chaux A, Vaghasia AM, Taheri D, Karram S, Bezerra SM, Gonzalez Roibon N, Nelson WG, Yegnasubramanian S, Netto GJ, Haffner MC.

PLoS One. 2016 Jan 19;11(1):e0146302. doi: 10.1371/journal.pone.0146302. eCollection 2016.

36.

Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.

Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks JL, Bianchi-Frias D, Horn LA, Kulac I, Moubarek MS, Nelson PS, Yegnasubramanian S, De Marzo AM, Bieberich CJ.

Cancer Res. 2016 Jan 15;76(2):283-92. doi: 10.1158/0008-5472.CAN-14-3280. Epub 2015 Nov 10.

37.

GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress.

Mian OY, Khattab MH, Hedayati M, Coulter J, Abubaker-Sharif B, Schwaninger JM, Veeraswamy RK, Brooks JD, Hopkins L, Shinohara DB, Cornblatt B, Nelson WG, Yegnasubramanian S, DeWeese TL.

Prostate. 2016 Feb;76(2):199-206. doi: 10.1002/pros.23111. Epub 2015 Oct 8.

38.

Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.

Haffner MC, Weier C, Xu MM, Vaghasia A, Gürel B, Gümüşkaya B, Esopi DM, Fedor H, Tan HL, Kulac I, Hicks J, Isaacs WB, Lotan TL, Nelson WG, Yegnasubramanian S, De Marzo AM.

J Pathol. 2016 Jan;238(1):31-41. doi: 10.1002/path.4628. Epub 2015 Oct 14.

39.

Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.

Hurley PJ, Hughes RM, Simons BW, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kimura Y, Jabbari J, Ross AE, Erho N, Vergara IA, Faraj SF, Davicioni E, Netto GJ, Yegnasubramanian S, An SS, Schaeffer EM.

Cancer Res. 2015 Oct 15;75(20):4322-34. doi: 10.1158/0008-5472.CAN-15-0024. Epub 2015 Aug 20.

40.

Global DNA methylation changes and differential gene expression in Anaplasma phagocytophilum-infected human neutrophils.

Sinclair SH, Yegnasubramanian S, Dumler JS.

Clin Epigenetics. 2015 Jul 29;7:77. doi: 10.1186/s13148-015-0105-1. eCollection 2015.

41.

Should Gleason 6 be labeled as cancer?

Kulac I, Haffner MC, Yegnasubramanian S, Epstein JI, De Marzo AM.

Curr Opin Urol. 2015 May;25(3):238-45. doi: 10.1097/MOU.0000000000000165. Review.

42.

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR.

Sci Transl Med. 2015 Jan 7;7(269):269ra2. doi: 10.1126/scitranslmed.3010563.

43.

Regulatory T cell DNA methyltransferase inhibition accelerates resolution of lung inflammation.

Singer BD, Mock JR, Aggarwal NR, Garibaldi BT, Sidhaye VK, Florez MA, Chau E, Gibbs KW, Mandke P, Tripathi A, Yegnasubramanian S, King LS, D'Alessio FR.

Am J Respir Cell Mol Biol. 2015 May;52(5):641-52. doi: 10.1165/rcmb.2014-0327OC.

44.

Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer.

Khor TO, Fuentes F, Shu L, Paredes-Gonzalez X, Yang AY, Liu Y, Smiraglia DJ, Yegnasubramanian S, Nelson WG, Kong AN.

Cancer Prev Res (Phila). 2014 Dec;7(12):1186-97. doi: 10.1158/1940-6207.CAPR-14-0127. Epub 2014 Sep 29.

45.

Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas.

Tan HL, Haffner MC, Esopi DM, Vaghasia AM, Giannico GA, Ross HM, Ghosh S, Hicks JL, Zheng Q, Sangoi AR, Yegnasubramanian S, Osunkoya AO, De Marzo AM, Epstein JI, Lotan TL.

Mod Pathol. 2015 Mar;28(3):446-56. doi: 10.1038/modpathol.2014.115. Epub 2014 Sep 12.

46.

RNA-Seq of the nucleolus reveals abundant SNORD44-derived small RNAs.

Bai B, Yegnasubramanian S, Wheelan SJ, Laiho M.

PLoS One. 2014 Sep 9;9(9):e107519. doi: 10.1371/journal.pone.0107519. eCollection 2014.

47.

Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.

Lin MT, Mosier SL, Thiess M, Beierl KF, Debeljak M, Tseng LH, Chen G, Yegnasubramanian S, Ho H, Cope L, Wheelan SJ, Gocke CD, Eshleman JR.

Am J Clin Pathol. 2014 Jun;141(6):856-66. doi: 10.1309/AJCPMWGWGO34EGOD.

48.

Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer.

Guerrero-Preston R, Michailidi C, Marchionni L, Pickering CR, Frederick MJ, Myers JN, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu VE, Sidransky D.

Epigenetics. 2014 Jul;9(7):1031-46. doi: 10.4161/epi.29025. Epub 2014 May 1.

49.

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.

Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, Chen Y, Ali A, Srinivasan A, McLeod DG, Yegnasubramanian S, Srivastava S, Dobi A, Petrovics G.

Epigenetics. 2014 Jun;9(6):918-27. doi: 10.4161/epi.28710. Epub 2014 Apr 2.

50.

Diagnostic challenges of clonal heterogeneity in prostate cancer.

Haffner MC, De Marzo AM, Yegnasubramanian S, Epstein JI, Carter HB.

J Clin Oncol. 2015 Mar 1;33(7):e38-40. doi: 10.1200/JCO.2013.50.3540. Epub 2014 Mar 17. No abstract available.

PMID:
24638011

Supplemental Content

Loading ...
Support Center